Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 2/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31438926 | 1.00 | CA1 (0.50) | CA1CA2CA9CA12CA3 | |
| Urea SCHEMBL28537123 | 0.93 | CA1 (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL12314741 | 0.90 | CA1 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL16238072 | 0.85 | LPL (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL10391 | 0.84 | HTT (0.49) | CA1CA2CA9CA12CA3 | |
| SCHEMBL14719219 | 0.84 | CA1 (0.47) | CA1CA2CA9CA12CA3 | |
| SCHEMBL21314553 | 0.84 | CA1 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL17160118 | 0.83 | CA2 (0.49) | CA1CA2CA9CA12CA3 | |
| SCHEMBL11894843 | 0.83 | HTR6 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL482278 | 0.82 | CA1 (0.55) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593172-B2 | Ziegler-natta catalyst systems comprising a 1,2-phenylenedioate as internal donor and process for preparing the same | INDIAN OIL CORPORATION LIMITED (IN) | 2017-03-14 | — | — | US | claimed |
| US-20150152199-A1 | ZIEGLER-NATTA CATALYST SYSTEMS COMPRISING A 1,2-PHENYLENEDIOATE AS INTERNAL DONOR AND PROCESS FOR PREPARING THE SAME | INDIAN OIL CORPORATION LIMITED (IN) | 2015-06-04 | — | — | US | claimed |
| EP-2872538-A1 | ZIEGLER-NATTA CATALYST SYSTEMS COMPRISING A 1,2-PHENYLENEDIOATE AS INTERNAL DONOR AND PROCESS FOR PREPARING THE SAME | Indian Oil Corporation Ltd (IN) | 2015-05-20 | — | — | EP | claimed |
| WO-2014013401-A1 | ZIEGLER-NATTA CATALYST SYSTEMS COMPRISING A 1,2-PHENYLENEDIOATE AS INTERNAL DONOR AND PROCESS FOR PREPARING THE SAME | INDIAN OIL CORPORATION LIMITED (IN) | 2014-01-23 | — | — | WO | claimed |
| CN-119725741-A | Electrolyte for lithium iron manganese phosphate system battery and lithium ion battery | 安徽得壹能源科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | NXERA PHARMA UK LIMITED (GB) | 2024-08-06 | — | — | US | disclosed |
| EP-3490970-B1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2023-09-13 | — | — | EP | disclosed |
| US-20230063230-A1 | NURR1 RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| EP-3927330-A1 | NURR1 RECEPTOR MODULATORS | The Regents of the University of California (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
| US-20070088016-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2006-03-23 | — | — | US | disclosed |
| WO-2005066153-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1519915-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004052847-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-6639107-B1 | Potentiating glutamate receptor function | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | CA1 4711/4885CA2 3699/4885CA9 4811/4885 |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | CA1 2937/4885CA2 1522/4885CA9 1272/4885 |
| US-20230063230-A1 | NURR1 RECEPTOR MODULATORS | NR2E3, NR4A2, NR0B1 | CA1 4527/4885CA2 4851/4885CA9 4866/4885 |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | CA1 3884/4885CA2 3527/4885CA9 4797/4885 |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2A, ADORA2B, ADORA1 | CA1 1951/4885CA2 2570/4885CA9 4728/4885 |
| US-20070088016-A1 | Tricyclic steroid hormone nuclear receptor modulators | NR3C2, NR3C1, NR5A1 | CA1 2840/4885CA2 1565/4885CA9 2730/4885 |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | CA1 1383/4885CA2 3445/4885CA9 4783/4885 |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR3C1 | CA1 2966/4885CA2 1845/4885CA9 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.